428 related articles for article (PubMed ID: 30481785)
61. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance.
Li B; Chen H; Wu N; Zhang WJ; Shang LX
Int J Gynecol Cancer; 2014 Oct; 24(8):1381-8. PubMed ID: 25248111
[TBL] [Abstract][Full Text] [Related]
62. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
Guo P; Xiong X; Zhang S; Peng D
Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
[TBL] [Abstract][Full Text] [Related]
63. Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer.
Bortot B; Mongiat M; Valencic E; Dal Monego S; Licastro D; Crosera M; Adami G; Rampazzo E; Ricci G; Romano F; Severini GM; Biffi S
Int J Nanomedicine; 2020; 15():4793-4810. PubMed ID: 32764921
[TBL] [Abstract][Full Text] [Related]
64. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
65. lncRNA TUG1-Mediated Mir-142-3p Downregulation Contributes to Metastasis and the Epithelial-to-Mesenchymal Transition of Hepatocellular Carcinoma by Targeting ZEB1.
He C; Liu Z; Jin L; Zhang F; Peng X; Xiao Y; Wang X; Lyu Q; Cai X
Cell Physiol Biochem; 2018; 48(5):1928-1941. PubMed ID: 30092578
[TBL] [Abstract][Full Text] [Related]
66. shRNA-mediated AMBRA1 knockdown reduces the cisplatin-induced autophagy and sensitizes ovarian cancer cells to cisplatin.
Li X; Zhang L; Yu L; Wei W; Lin X; Hou X; Tian Y
J Toxicol Sci; 2016 Feb; 41(1):45-53. PubMed ID: 26763392
[TBL] [Abstract][Full Text] [Related]
67. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
68. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer.
Li J; Jiang K; Qiu X; Li M; Hao Q; Wei L; Zhang W; Chen B; Xin X
BMB Rep; 2014 Jan; 47(1):33-8. PubMed ID: 24209634
[TBL] [Abstract][Full Text] [Related]
69. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
70. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
[TBL] [Abstract][Full Text] [Related]
71. ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells.
Xie Q; Su J; Jiao B; Shen L; Ma L; Qu X; Yu C; Jiang X; Xu Y; Sun L
Int J Oncol; 2016 Dec; 49(6):2507-2519. PubMed ID: 27748803
[TBL] [Abstract][Full Text] [Related]
72. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
73. HOXB9 Overexpression Confers Chemoresistance to Ovarian Cancer Cells by Inducing ERCC-1, MRP-2, and XIAP.
Suh DH; Park WH; Kim M; Kim K; No JH; Kim YB
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674764
[TBL] [Abstract][Full Text] [Related]
74. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
75. Correlations of the ZEB1 expression with the incidence and prognosis of non-small cell lung cancer.
Ma DJ; Liu HS; Li SQ; Qin YZ; He J; Li L; Cui YS
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1528-1535. PubMed ID: 30840275
[TBL] [Abstract][Full Text] [Related]
76. CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1.
Luo H; Zhou Z; Huang S; Ma M; Zhao M; Tang L; Quan Y; Zeng Y; Su L; Kim J; Zhang P
Cell Death Dis; 2021 Aug; 12(9):820. PubMed ID: 34462429
[TBL] [Abstract][Full Text] [Related]
77. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
78. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
79. Alpha2,3-sialyltransferase III knockdown sensitized ovarian cancer cells to cisplatin-induced apoptosis.
Wang X; Zhang Y; Lin H; Liu Y; Tan Y; Lin J; Gao F; Lin S
Biochem Biophys Res Commun; 2017 Jan; 482(4):758-763. PubMed ID: 27871859
[TBL] [Abstract][Full Text] [Related]
80. PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment.
Zhu X; Ji M; Han Y; Guo Y; Zhu W; Gao F; Yang X; Zhang C
Int J Oncol; 2017 Mar; 50(3):835-846. PubMed ID: 28197632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
